Business
Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients GloballyCalgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia \"CLI\" and peripheral arterial disease \"PAD\" patients, globally. The purpose of the revisions are to engage with CLI and PAD patients, to provide them with ACP-01 as limb saving treatment, and to provide them with strategies that may improve their quality of life. For example, when an individual seeks a solution to PAD or CLI, the Hemostemix site will be the first website that they obtain. Within the CLI landing page, it will contain the following information:ACP-01 treatment options and the regulatory pathway to obtain a compassionate treatment exemption.The healthcare protocols that were followed by patients in the ACP-01 CLI clinical trial that led to the dramatic reductions of amputations, as compared to \"normal care\" for this patient population.Patient testimonials of the outcomes of an ACP-01 exempt compassionate treatment.A portal for peer to peer engagement, including peer to peer coaching led by a Hemostemix coach who is familiar with the no-option patient population.\"Hemostemix' ACP-01 CLI wound healing and amputation data describes saving 93.5% of treated limbs from amputation, and a dramatic reduction of the size and and magnitude of ulcers in the treated population,\" stated Thomas Smeenk, CEO. \"Many of the Principle Investigators of the CLI clinical trial have commented to me that the clinical trial protocol, as compared to normal care of the no-option patient population, led to dramatic differences, and that it should be implemented as a way to help improve patients' lives. So, that is what we are going to offer while we also offer ACP-01 as an exempt compassionate treatment,\" Smeenk said. ACP-01 is a safe and effective cell therapy for the treatment of CLI, a loss of circulation (atherosclerosis) in the limbs that leads to severe pain, ulcerating wounds, gangrene and amputation. ACP-01 has completed a Phase II clinical trial for CLI. In the 17 center Phase II ...